Company Novus Therapeutics, Inc. Nasdaq
Equities
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 20-04-30 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 21-03-14 |
Steven Perrin
PSD | President | 59 | 20-09-13 |
Eliezer Katz
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-22 |
John Herberger
CTO | Chief Tech/Sci/R&D Officer | - | 22-04-30 |
Bryan Smith
CMP | Compliance Officer | 45 | 21-04-18 |
David Hovland
LAW | General Counsel | - | 21-04-18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 17-04-30 |
John McBride
BRD | Director/Board Member | 72 | 17-04-30 |
Steven Perrin
PSD | President | 59 | 20-09-13 |
Chief Executive Officer | 52 | 20-04-30 | |
James Robinson
BRD | Director/Board Member | 54 | 23-09-30 |
June Lee
BRD | Director/Board Member | 58 | 20-12-08 |
Jan Hillson
BRD | Director/Board Member | 71 | 21-07-01 |
Allan Kirk
BRD | Director/Board Member | 62 | 23-10-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 110,086 | 0 | 0 | 96.49 % |
Stock B | 1 | 38,506,614 | 37,155,255 ( 96.49 %) | 0 | |
Stock C | 0 | 4,422 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |